JP2018530606A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530606A5
JP2018530606A5 JP2018536071A JP2018536071A JP2018530606A5 JP 2018530606 A5 JP2018530606 A5 JP 2018530606A5 JP 2018536071 A JP2018536071 A JP 2018536071A JP 2018536071 A JP2018536071 A JP 2018536071A JP 2018530606 A5 JP2018530606 A5 JP 2018530606A5
Authority
JP
Japan
Prior art keywords
vitamin
polysaccharide
activity
biological function
micelle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530606A (ja
JP6877049B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053626 external-priority patent/WO2017053920A1/en
Publication of JP2018530606A publication Critical patent/JP2018530606A/ja
Publication of JP2018530606A5 publication Critical patent/JP2018530606A5/ja
Application granted granted Critical
Publication of JP6877049B2 publication Critical patent/JP6877049B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536071A 2015-09-25 2016-09-25 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤 Active JP6877049B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233112P 2015-09-25 2015-09-25
US62/233,112 2015-09-25
PCT/US2016/053626 WO2017053920A1 (en) 2015-09-25 2016-09-25 Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

Publications (3)

Publication Number Publication Date
JP2018530606A JP2018530606A (ja) 2018-10-18
JP2018530606A5 true JP2018530606A5 (enExample) 2019-12-12
JP6877049B2 JP6877049B2 (ja) 2021-05-26

Family

ID=58387558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536071A Active JP6877049B2 (ja) 2015-09-25 2016-09-25 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤

Country Status (9)

Country Link
US (2) US10517961B2 (enExample)
EP (1) EP3352796B1 (enExample)
JP (1) JP6877049B2 (enExample)
KR (1) KR20180058759A (enExample)
CN (1) CN108135917B (enExample)
AU (1) AU2016326747A1 (enExample)
CA (1) CA2995029C (enExample)
IL (1) IL257652A (enExample)
WO (1) WO2017053920A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197100A1 (en) 2015-06-04 2016-12-08 Crititech, Inc. Nozzle assembly and methods for use
PT3439635T (pt) 2016-04-04 2021-02-11 Crititech Inc Formulações para tratamento de tumores sólidos
KR20200014279A (ko) * 2017-06-09 2020-02-10 크리티테크, 인크. 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック,インコーポレイテッド 肺障害の治療方法
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
CN113382643A (zh) * 2018-11-20 2021-09-10 斯菲拉封装有限责任公司 多层颗粒
CN111956806B (zh) * 2020-09-03 2023-04-07 四川大学 一种药物载体、胶束、药剂及其制备方法和应用
KR102619293B1 (ko) * 2021-01-14 2023-12-29 주식회사 엔바이오스 Sp-fa 접합체를 유효성분으로 함유하는 항암용 조성물
CN113082219B (zh) * 2021-04-07 2023-02-17 中国科学院大学温州研究院(温州生物材料与工程研究所) 一种基于π-π作用的疏水药物的增溶方法
CN118477122B (zh) * 2024-07-16 2024-09-24 中科创导(山东)生物科技有限公司 一种混合酶发酵生产治疗眼疾的中药制剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
CA2084194C (en) 1991-04-02 2003-05-20 Gregory John Russell-Jones Oral delivery systems for microparticles
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
CA2071160A1 (en) 1991-07-31 1993-02-01 Vittorio Farina Asymmetric synthesis of taxol side chain
SG46582A1 (en) 1991-09-23 1998-02-20 Univ Florida State 10-Desacetoxytaxol derivatives
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌/抗ウイルス性化合物原料としてのイチイ培養組織
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
US5380751A (en) 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
WO1994020089A1 (en) 1993-03-09 1994-09-15 Enzon, Inc. Taxol-based compositions with enhanced bioactivity
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5449720A (en) 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5395850A (en) 1994-03-10 1995-03-07 Bristol-Myers Squibb Company 6,7-epoxy paclitaxels
NZ322318A (en) 1995-11-02 2000-01-28 Glaxo Wellcome Inc Method for preparing camptothecin derivatives
GB9600438D0 (en) 1996-01-10 1996-03-13 Pharmacia Spa Hexacyclic camptothecin analogues, and process for preparing them
GB9601779D0 (en) 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
GB9702807D0 (en) 1997-02-12 1997-04-02 Pharmacia & Upjohn Spa Alkynyl-substituted camptothecins and process for their preparation
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
US5977348A (en) 1997-07-25 1999-11-02 National Starch And Chemical Investment Holding Corporation Polysaccharide modification in densified fluid
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
PT1044977E (pt) 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
EP1183487B1 (de) 1999-05-18 2007-01-17 Powerpulse Holding AG Strahlungsleiteinrichtung
US20030100553A1 (en) 2000-02-29 2003-05-29 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with camptothecin compounds
GB0008928D0 (en) 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6689338B2 (en) 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
WO2002067995A1 (en) 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
US20030157161A1 (en) 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
WO2003101406A1 (en) 2002-06-03 2003-12-11 California Pacific Medical Center Homo-camptothecin derivatives
US6759416B2 (en) 2002-08-06 2004-07-06 Panorama Research, Inc. Anticancer conjugates of camptothecin and unsaturated fatty acids
WO2010002982A1 (en) * 2008-07-01 2010-01-07 Cognosci, Inc. Methods of treating cancer with apoe peptides
JP2010126533A (ja) 2008-11-28 2010-06-10 Bio Verde:Kk 高機能化抗癌剤
AU2010234916A1 (en) 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2012030745A1 (en) 2010-08-30 2012-03-08 Access Pharmaecuticals, Inc MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS
US20120231069A1 (en) * 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US8968790B2 (en) 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
CN103992417A (zh) * 2012-12-14 2014-08-20 苏州友林生物科技有限公司 用于包裹药物化合物的辅料的制备方法及该辅料
CN103936880A (zh) * 2012-12-14 2014-07-23 苏州友林生物科技有限公司 纳米级颗粒型辅料
CN103120794B (zh) * 2012-12-14 2014-04-30 苏州友林生物科技有限公司 协同起效的药用辅料及其抗肿瘤应用
CN104434792B (zh) * 2013-09-12 2018-03-23 中国科学院深圳先进技术研究院 聚合物胶束及其制备方法和抗肿瘤药物组合物、制剂及其制备方法
WO2015126841A1 (en) 2014-02-18 2015-08-27 Plasmatech Biopharmaceuticals, Inc. Nutritional and therapeutic mucoadhesive formulations

Similar Documents

Publication Publication Date Title
JP2018530606A5 (enExample)
Farboudi et al. UiO-66 metal organic framework nanoparticles loaded carboxymethyl chitosan/poly ethylene oxide/polyurethane core-shell nanofibers for controlled release of doxorubicin and folic acid
Wang et al. Self‐assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy
Chen et al. EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide
CN103030140A (zh) 透明质酸修饰的氧化石墨烯及其药物组合物的制备方法与应用
JP6877049B2 (ja) 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤
Sugahara et al. Complete regression of xenografted human carcinomas by a paclitaxel–carboxymethyl dextran conjugate (AZ10992)
RU2008112144A (ru) Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
JP2011507838A5 (enExample)
KR20170007780A (ko) 미셀 나노복합체
CN105012271B (zh) 一种共担载阿霉素和trail的白蛋白纳米粒靶向制剂及制备方法
SI2231189T1 (en) A delivery system for administering pharmaceutical active substances that are poorly soluble in water
CN105267979B (zh) 聚合法制备棉酚及其衍生物聚多巴胺纳米载体的方法
CN102370622A (zh) 一种载药物纳米粒及其制备方法和应用
Ebrahimnejad et al. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38
CN105879052B (zh) 一种果胶-多臂聚乙二醇自组装制备纳米药物的方法
Osmani et al. Cyclodextrin nanosponges in drug delivery and nanotherapeutics
CN110665009B (zh) 一种促肿瘤血管正常化纳米化吉西他滨及其应用
CN103301073B (zh) 一种甲氨喋呤靶向纳米粒缓释制剂及其制备方法
JP2011507840A5 (enExample)
Lv et al. Influence of unsaturated fatty acids on the antitumor activity of polymeric conjugates grafted with cabazitaxel against prostate cancer
ITMI20071321A1 (it) Nanospugne a base di ciclodestrine come veicolo per farmaci antitumorali
CN109666087B (zh) 一种环糊精类衍生物及其制备方法与应用
Miao et al. Preparation of DOX/BSANP and its antitumor effect on bel-7404 liver cancer cells in vitro and in vivo
CN102078302B (zh) 一种小檗胺壳聚糖-琼胶纳米粒的制备方法